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Dermatological disease has been shown to be associated 
with psychological comorbidity. The aim of this observa-
tional study is to describe the distribution of skin disease 
and the prevalence of depression, anxiety and stress 
among Norwegian dermatological outpatients. Thirteen 
percent of outpatients had clinical anxiety compared 
with 3.7% of healthy controls, and 5.8% had clinical de-
pression compared with 0.9% of controls. Adjusted odds 
ratio for clinical anxiety was 4.53 in patients compared 
with controls, and for clinical depression 6.25, which is 
much higher than previously described in a larger Euro-
pean study. Patients with tumours had less depression. 
Chronic inflammatory skin conditions had an especially 
high impact on patient’s psychological wellbeing and 
should not be undervalued relative to, for instance, skin 
cancer in health strategies. These results argue strongly 
for including skin disease prevention and treatment in 
future health strategies. Key words: depression; anxiety; 
psychiatric comorbidity; distribution of dermatological di-
sease; skin cancer; chronic skin diseases.
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Skin conditions are common in the community (1), but 
their distribution and association with psychological 
problems are not fully known. There are studies on the 
prevalence of the separate dermatological diseases, but 
few on the distribution of common skin diseases among 
dermatological outpatients (1, 2).
The most prevalent conditions in dermatology are the 
chronic inflammatory diseases. Psoriasis, eczemas, acne 
and hand eczema have a combined prevalence of approx-
imately 25% in developed countries, followed by non-
melanoma skin cancer and precancerous conditions (3).
From community studies in Norway (4, 5) and other 
countries (6–8), we know that individuals with itchy skin, 
eczema and psoriasis are twice as likely to be depressed as 
the general population (9). Our group has recently shown 
that comorbid depression, anxiety and suicidal ideation 
are common in patients with skin conditions (10). 
Depression, anxiety, stress and negative life events 
have been demonstrated to trigger chronic skin disease 
and can further worsen the skin condition through low 
compliance and lack of adherence to the treatment re-
gimen (11, 12). Suicidal ideation is more common in 
patients with depression, which may be pre-existing, 
appear as a complication to the skin condition or be 
triggered by the dermatological medication (13–15). 
Overall mortality is relatively low for skin diseases, 
but further research is needed into suicide related to 
dermatological disease.
The aim of this study is to describe the distribution 
of skin diseases, specifically among Norwegian outpa-
tients, and to study the association between depression, 
anxiety and stress for different skin conditions, especi-
ally benign tumours, cancer, precancerous lesions and 
chronic recurrent skin diseases compared with healthy 
controls.
METHODS
This is an observational case-controlled study. Patients were 
recruited from 2 Norwegian dermatological outpatient clinics: 
Stavanger University Hospital and Oslo University Hospital, 
Department of Dermatology during the period November 2011 
to February 2013. This present study is part of a larger European 
multi-centre study (10).
The study protocol was approved by the Regional Committee 
for Medical Research Ethics in Norway in August 2011 and the 
study was performed in full accordance with the World Medical 
Association’s Declaration of Helsinki.
Consecutive patients were invited to participate on random 
days at each centre. The patients were informed about the 
study by a research assistant just before their consultation and 
provided written consent. Inclusion criteria were: age over 18 
years; able to read and write Norwegian; and not having a di-
agnosed severe mental disease. Each participant in the patient 
group was handed 5 questionnaires, which they returned to the 
consultant on entering the consultation room. The first part of 
the questionnaire included socio-demographic variables, such 
as sex, age, ethnicity, education, self-reported socio-economic 
status, economic difficulties during the last 5 years and stressful 
life events during the last 6 months.
Symptoms of depression and anxiety were assessed with the 
Hospital Anxiety and Depression Scale (HADS). This scale is 
widely used among patients in hospital settings (16); it includes 
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7 items for assessing anxiety and 7 items for depression with 
4 possible answers each. For each dimension of anxiety and 
depression, a score of 0–7 is considered normal, 8–10 marginal, 
and 11–21 clinical depression or clinical anxiety. 
A clinical examination was performed by the dermatologist 
for each patient and an objective assessment sheet was comple-
ted after the examination including the dermatological diagno-
sis. Physical co-morbidities were registered by the clinician if 
the patient had treatment for any of the following conditions: 
cardiovascular disease, chronic respiratory disease, diabetes 
mellitus, rheumatological disease, or other. In the control 
group, information on treated comorbidities was self-reported.
The control group was recruited on a voluntary basis at each 
centre from among employees of the service division of the 
hospital. They returned the completed questionnaires to the 
researcher. The controls were not examined clinically.
Patients in the current study presented a high variety of 
diagnoses, arranged into 27 groups. Skin diseases can be gene-
ralized, chronic and extensive, need long-term treatments and 
are perhaps incurable (eczemas, psoriasis, pruritic conditions, 
connective tissue disease, chronic ulcers, chronic infections 
and alopecias). Other conditions, however, are solitary, non-
extensive, without periods of exacerbation in their course and 
mostly have radical short-term treatments (benign tumours, 
naevi, non-melanoma skin cancer (NMSC) and malignant mela-
noma), or need no treatment at all. For the purpose of regression 
analysis, we merged the skin conditions into 2 categories: the 
chronic, recurrent, inflammatory conditions and solitary lesions 
(tumours, cancers, melanoma and precancerous lesions) (17). 
In our outpatient population, only a few conditions could not 
be classified as belonging to either of the 2 groups.
It is important to note that patients with malignant melanoma 
and skin cancer in our clinics may be quite different from pa-
tients seen by dermatologists in other countries. Our patients 
would be consulted in outpatient clinics mainly for primary 
diagnostics, primary excisions, and, to a lesser degree, for 
extensive re-excisions or complex oncological treatments. 
Metastatic melanoma or metastatic skin cancer were not re-
presented in our study. The data thus truly reflects how 
patients with solitary, uncomplicated lesions are affected 
compared with extensive chronic disease, specifically 
outpatients in Norway.
Statistical analysis
SPSS version 22 software was used. Continuous vari-
ables were analysed in terms of difference between the 
means, using t-test and analysis of variance (ANOVA). 
Dichotomous variables were analysed in terms of dif-
ference between proportions, using the χ2 test. Bivariate 
and multivariate logistic regression models were tested 
to study the associations between variables, simultan-
eously controlling for potential confounding factors. For 
regression analyses, diagnoses were grouped into 2 large 
groups, as described above.
RESULTS
The total number of participants was 795, with 
577 patients and 218 controls (Table I). The par-
ticipation rate of the patients was 91.3%. There 
were more females in both groups. The mean age 
of the patients was 50.1 years. The distribution ac-
cording to socio-economic level was comparable 
in the 2 groups. Compared with controls, patients 
had a slightly lower education and had more comor-
bidities regarding cardiological, rheumatological and 
other diseases, but not respiratory diseases or diabetes 
mellitus. More than one-third (35.3%) of the patients 
had at least one comorbidity vs. 15.6% of the controls.
The overall distribution of skin diseases is presented 
in Table II. The most common diagnosis overall, and 
for both sex, was psoriasis (21%), followed by NMSC 
(10.6%) and actinic keratosis (AK) (8.7%). The chronic 
inflammatory dermatoses accounted for nearly half of 
our patients’ pathology (44.9%). Together with other 
itchy dermatoses and hand dermatoses the chronic in-
flammatory skin conditions accounted for more than 
half (55.6%) of the pathology in our dermatological 
population. When adding the rest of the chronic condi-
tions to this group (e.g. autoimmune disorders, chronic 
infections, chronic ulcers, alopecias, hyperhidrosis and 
monogenetic diseases), we see that 69.3% of the condi-
tions in our Norwegian outpatients are chronic, recurrent 
and mainly inflammatory diseases.The benign tumours, 
naevi and actinic keratosis accounted for 14.1% of the 
skin conditions, while skin cancer and malignant mela-
noma accounted for 14.2%. 
Table SI1 shows the percentages of depression, anxiety 
and stress. Significantly more patients were depressed 
(HADS ≥ 8) compared with controls (13.3% vs. 5.6%). 
Among those, significantly more had a clinical depres-
sion (5.8% of the patients vs. 0.9% of the controls) defi-
ned as HADS ≥ 11. Anxiety as HADS ≥ 8 was registered 




n = 218 p-value
Sex, n (%)
   Female




  68 (31.3) 
< 0.05
Age years, mean (SD) [range]
   Females 
   Males
  50.1 (17.7) [18–92]
  49.2 (17.7)
  51.2 (17.8)
  42.2 (12.5) [19–67]
  43.6 (12.8)




Socio-economic status, n (%)
   Low
   Middle
   High
  69 (12.8)
407 (75.5)
  63 (11.7)
  29 (13.5)
168 (78.1)
  18 (8.4)
NS
Educational level, n (%)
   Lower
   Higher or university
  82 (15.2)
457 (84.7)
  16 (7.5)
197 (92.5)
< 0.05
Economic difficulties, n (%)
   Yes
   No
  64 (11.9)
472 (88.1)
  19 (8.8)
196 (91.2)
NS
Physical comorbidities, n (%)
   Yes 200 (35.3)   33 (15.6) < 0.05
Cardiovascular, n (%) 128 (23.3)   10 (4.7) < 0.05
Respiratory, n (%)   39 (7.2)   16 (7.6) NS
Diabetes, n (%)   28 (5)     5 (2.4) NS
Rheumatological, n (%)   68 (12.3)     9 (4.3) < 0.05
Other comorbidities, n (%) 141 (25.2)   18 (8.9) < 0.05
Missing values: patients 1–41; controls 1–6.
1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-2200
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in 27.1% of the patients and 14.8% of the controls, while 
13% of the patients had clinical anxiety (HADS ≥11) vs. 
3.7% of the controls. Experienced stress was 30.1% for 
patients vs. 20.1% for controls. Patients with tumours, 
cancer and precancerous lesions, however, did not show 
any significant difference in depression, anxiety and 
stress compared with the healthy controls. On the other 
hand, nearly a third of the patients with chronic recurrent 
dermatoses were anxious or experienced stress.
In Table III we present odds ratio (OR) with 95% 
confidence interval (95% CI) for Norwegian outpatients 
to have depression, anxiety and stress, all adjusted for 
age, sex, socio-economic status, education and physical 
comorbidity. Compared to the figures from a European 
study (10) patients had more than 3 times higher odds to 
be depressed than healthy controls (OR 3.12), nearly 3 
times higher odds for anxiety (OR 2.87) and experienced 
twice as much stress (OR 2.1). The odds for clinical de-
pression and clinical anxiety were even higher, showing 
that the odds for patients to be clinically depressed was 
6.25, and to have clinical anxiety 4.53. Norwegian der-
matological outpatients have odds 2 and 3 times higher 
for anxiety and depression compared with controls than 
do patients from other European countries.
Especially high odds for depression were seen among 
patients with chronic, inflammatory, recurrent skin con-
ditions with OR as high as 7.3, confirming significant 
psychological suffering in this group. Patients with 
benign or malignant solitary lesions showed 2-fold 
higher odds to experience stress (OR 1.95) and anxiety 
(OR 2.18). The odds for depression were not higher 
than for controls (OR 1), and only just slightly higher 
for clinical depression (OR 1.38) (Table III).
DISCUSSION
In this Norwegian study we found that the most com-
mon conditions among dermatological outpatients 
were psoriasis and NMSC, followed by AK. More than 
two-thirds of the patients had a chronic inflammatory 
skin condition. The distribution of skin diseases in our 
study shows prevalence rates similar to these described 
in other European countries (1). A European multicentre 
study found the same 2 diseases, psoriasis and NMSC, 
to be most common among dermatological outpatients 
in Europe (10). In accordance with the European study, 
our study showed clinical depression and clinical anx-
iety to be significantly higher for patients compared 
Table II. Distribution of skin diseases in a Norwegian sample of dermatological outpatients (n = 577). Distribution of skin disease by 
sex (n = 576)
Diagnosisa
All 
n = 577 
n (%)
Male 
n = 240 
n (%)
Female 
n = 336 
n (%)
1 Psoriasis 121 (21) 65 (27.1) 56 (16.7)
2 Non-melanoma skin cancer 61 (10.6) 24 (10) 37 (11)
3 Actinic keratosis 50 (8.7) 16 (16.7) 34 (10.1)
4 Eczemas and contact allergy 39 (6.8) 13 (5.4) 25 (7.4)
5 Acne 31 (5.4) 13 (5.4) 18 (5.4)
6 Atopic dermatitis 31 (5.4) 13 (5.4) 18 (5.4)
7 Naevi and benign tumours 31 (5.4) 9 (3.8) 21 (6.3)
8 Rosacea, perioral dermatitis, facial erythema 27 (4.7) 5 (2.1) 22 (6.5)
9 Autoimmune diseasesb 23 (4) 8 (3.3) 15 (4.5)
10 Malignant melanoma 21 (3.6) 8 (3.3) 13 (3.9)
11 Hand eczema 19 (3.3) 11 (4.6) 8 (2.4)
12 Pustulosis palmoplantaris 17 (2.9) 6 (2.5) 11 (3.3)
13 Infections (not venereal) 17 (2.9) 9 (3.8) 8 (2.4)
14 Urticaria 13 (2.3) 6 (2.5) 7 (2.1)
15 Pruritus and prurigo 13 (2.3) 7 (2.9) 6 (1.8)
16 Ulcus cruris, stasis dermatitis and chronic venous insufficiency 10 (1.3) 5 (2.1) 5 (1.5)
17 Genital, not venereal 9 (1.6) 6 (2.5) 3 (0.9)
18 Monogenetic conditionsc 8 (1.4) 1 (0.4) 7 (2.1)
19 Otherd 8 (1.4) 2 (0.8) 6 (1.8)
20 Vitiligo 6 (1) 3 (1.3) 3 (0.9)
21 Seborrhoeic dermatitis 5 (0.9) 5 (2.1) 0
22 Hidradenitis suppurativa 4 (0.7) 2 (0.8) 2 (0.6)
23 Sarcoidosis and granuloma 3 (0.5) 1 (0.4) 2 (0.6)
24 Lichen planus 3 (0.5) 1 (0.4) 2 (0.6)
25 Alopecias 3 (0.5) 0 3 (0.9)
26 Pyoderma gangrenosum 2 (0.3) 0 2 (0.6)
27 Hyperhidrosis 2 (0.3) 1 (0.4) 1 (0.3)
aSome of the monogenetic and some of the genital conditions were classified as “inflammatory”, while other monogenetic and genital were classified as 
“solitary” for the purpose of regression analysis in order to give more correct values. Numbers in Table II will thus slightly vary from those given for the 
regression analysis. bAutoimmune disease: connective tissue disease, vasculitis, autoimmune blistering. cMonogenetic conditions: 2 Hailey-Hailey; 1 tuberous 
sclerosis; 1 microtia; 1 ichthyosis linearis circumflexa; 1 congenital malformation of face and neck; 1 vascular malformations (male); 1 Morbus Darier. 
dOther: 6 unspecified skin conditions, 1 cheilitis (female), 1 dermatitis artefacta (female).
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with the healthy controls, with more than 4-fold higher 
odds for clinical anxiety and 6-fold higher odds for 
clinical depression, i.e. higher than for the European 
study (2.2. and 2.4, respectively). The extent of psy-
chiatric comorbidity may vary between countries, or 
may reflect differences in patient populations. Further 
studies addressing this difference may be warranted.
Chronic, recurrent and more extensive skin conditions 
would be expected to affect a patient’s wellbeing diffe-
rently from solitary lesions (17–20). According to multi-
ple studies (5, 7, 8, 14, 15, 21–27), patients with chronic 
inflammatory and pruritic generalized dermatoses score 
highest for depression and anxiety. Other studies show 
that patients with cancer, tumours and pre-cancerous 
lesions experience less psychiatric comorbidity from 
their skin disease (18, 19), surprisingly, even for serious 
conditions such as malignant melanoma, especially in 
the early stages (28, 29). In an older study by Cassileth 
et al. (20) patients with malignant melanoma were stri-
kingly superior to other dermatology patients in terms 
of emotional well-being, perhaps because of the better 
support they receive. Shah & Coates (17) found that 
older patients with rashes suffered significantly more 
than did older patients with solitary lesions, even when 
the lesion was malignant. When grouping our patients in 
the same 2 categories we found a significant difference 
in psychiatric comorbidity compared to healthy control 
with each of these 2 categories. 
Odds for depression in patients with chronic recurrent 
skin diseases were more than 3-fold higher compared 
with healthy controls, nearly as much for anxiety and 
2-fold for stress. Odds for clinical depression and 
clinical anxiety in the same patient group showed even 
higher values. Especially high were odds for clinical 
depression, 7 times higher (OR 7.31) than for the 
healthy controls, confirming a significant impact on 
dermatological patients’ mental health. This finding 
may be of significance as dermatological units increase 
their focus on prioritizing cancer, thus generating longer 
waiting times for patients with other skin conditions.
The group of patients with tumours, NMSC, ma-
lignant melanoma and pre-cancerous lesions in our 
study showed no difference in odds for depression. 
Few studies have evaluated psychiatric comorbidity in 
patients with benign tumours, NMSC and AK, but our 
study shows results in accordance with other existing 
studies (17). Less psychiatric comorbidity in patients 
with solitary lesions compared with our other patients 
might reflect the more radical, surgical treatment op-
tions for skin cancer, AK, malignant melanoma and 
other tumours. Patients who were newly referred might 
not have been aware of the seriousness of their diagno-
sis. Their answers to the questionnaires reflect the true 
extent of discomfort solitary lesions present, usually 
not being itchy, painful or generalized.
There was no difference in depression, anxiety and 
stress even when analysing separately for malignant and 
benign tumours (data not shown). Malignant melanoma 
may be regarded as a more distinct condition because 
of its serious prognosis, but besides higher experienced 
stress, patients with malignant melanoma did not show 
more depression. We therefore included them in the 
group of solitary lesions, precisely to show that solitary 
lesions with more radical treatment and shorter course, 
even when serious, have a lower impact on a patient’s 
mental state, at least in the initial stages. 
Study limitations and strengths2
In conclusion, the most common skin conditions among 
dermatological outpatients in Norway are psoriasis and 
NMSC. Overall, dermatological patients have signifi-
cantly more psychiatric comorbidities, but this is not 
the case for patients with benign tumours, skin cancer 
and precancerous lesions. Chronic skin conditions have 
a high impact on patients’ psychological wellbeing and 
should not be undervalued relative to skin cancer in 
health strategies and waiting lists. These findings have 
implications for care management and prioritizing 
dermatological patients.
Table III. Logistic regression analysis with odds ratio (OR) and 95% confidence interval (95% CI) for being an outpatient compared 
with healthy controls for depression, anxiety and stressful life events. Adjusted for age, sex, education, social status and comorbidities
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Missing controls Norway: anxiety and depression: 8, stress: 11. Missing controls Europe: anxiety: 9, depression: 7.
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2Limitations: The patient and control groups were not case-matched. Still, there 
was no significant difference in socio-economic status and economic difficulties 
between the 2 groups. The staff at the hospital was over-represented by females 
and younger individuals. Employed personnel would be expected to be healthier 
than patients, but we intentionally aimed to have a control group, which would 
best match the World Health Organization (WHO)’s definition of health (30). 
The results for psychiatric comorbidity in the group with solitary lesions are 
precisely valid for Norwegian dermatological outpatients, since we would 
consult patients with malignant melanoma or skin cancer only in the initial 
phase of their disease. We cannot conclude that those patients will not develop 
more significant psychiatric symptoms during the course of their disease; a 
depression may need time to evolve. The results may be less applicable to other 
countries, but do pose interesting questions that may warrant further studies.
Strengths: There are few recent studies on the distribution of skin diseases 
in dermatological outpatients. We present here data on a patient population 
from 2 large dermatological clinics in Norway. This is the first study on 
depression, anxiety and stress among outpatients with common skin conditions 
compared with controls.
We further evaluated psychiatric comorbidity according to the 2 main 
diagnostic categories; chronic, recurrent skin conditions and solitary lesions, 
showing the large psychological impact chronic skin conditions have. There 
are few other studies comparing those 2 very different categories. The 
significant higher psychiatric comorbidity in the former group may open 
for better prioritizing, support and resource allocation for all dermatological 
patients, not only those with a malignant disease.
We have the opportunity to compare our results with the European study as 
a whole. Depression and anxiety are higher for dermatological outpatients in 
Norway, warranting further studies on depression and anxiety in Norwegian 
dermatological outpatients. We encourage other European countries to 
evaluate these issues, as numbers may vary widely from country to country.
Acta Derm Venereol 96
